12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR014 trial in 116 chemotherapy-naïve patients with stage IIIb/IV NSCLC showed that 0.8 µg/m 2 NGR-hTNF every 3 weeks plus cisplatin and pemetrexed or gemcitabine led to a median PFS of 5.8 months vs. 5.7 months for cisplatin and pemetrexed or gemcitabine alone. Additionally, NGR-hTNF plus cisplatin and pemetrexed or gemcitabine...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >